Baxter International has entered into an agreement with BioMerieux to exclusively distribute a new acute kidney injury test in Europe and the U.S.
The Nephrocleartm CCL14 test is in development for use in assessing the risk of developing persistent severe acute kidney injury (AKI). The agreement is part of a previously announced collaboration between the companies to improve identification and treatment of AKI.
Both will share in-country commercialization, while BioMerieux will retain control over the regulatory approval process
